Lineage Cell Therapeutics, Inc.

US$1.02As of Sun 8 Nov 2026, 12:00 UTC
AMEX:LCTXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (10.18%)
Div yield —
ROE (60.06%)
Biotechnology
Beta (5Y) 1.69
PE TTM —
TSR TTM (46.88%)
Mkt cap US$258.0M
ROIC (238.28%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.03
0.65%
(69.93%)
Hold 4|6|8|11|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
8.89%
2.10%
1.41%
12.47%
Revenue$M
11.29
11.30
11.19
11.79
(7.75%)
(7.05%)
(5.17%)
1.38%
Peers (US$258.0M)
Cap (US$)
PE
259.2M
—
Capital
TTM
5Y
10Y
Leveragex
1.128
(0.080)
(0.057)
EBIT/Intx
2.507
3.002
2.668
Own earn%
74.04
35.91
40.94
Sh yield%
15.31
35.91
33.66
Owners
Insiders/Inst%
10.01
71.03
Short interest%
0.78
SBC / revenue%
1.94
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
14–19
$1 testx
—
Incr. ROIC%
1